GABAergic compensation in connexin36 knock-out mice evident during low-magnesium seizure-like event activity.
Gap junctions within the cerebral cortex may facilitate cortical seizure formation by their ability to synchronize electrical activity. To investigate this, one option is to compare wild-type (WT) animals with those lacking the gene for connexin36 (Cx36 KO); the protein that forms neuronal gap junctions between cortical inhibitory cells. However, genetically modified knock-out animals may exhibit compensatory effects; with the risk that observed differences between WT and Cx36 KO animals could be erroneously attributed to Cx36 gap junction effects. In this study we investigated the effect of GABA(A)-receptor modulation (augmentation with 16μM etomidate and blockade with 100μM picrotoxin) on low-magnesium seizure-like events (SLEs) in mouse cortical slices. In WT slices, picrotoxin enhanced both the amplitude (49% increase, p=0.0006) and frequency (37% increase, p=0.005) of SLEs; etomidate also enhanced SLE amplitude (18% increase, p=0.003) but reduced event frequency (25% decrease, p<0.0001). In Cx36 KO slices, the frequency effects of etomidate and picrotoxin were preserved, but the amplitude responses were abolished. Pre-treatment with the gap junction blocker mefloquin in WT slices did not significantly alter the drug responses, indicating that the reduction in amplitude seen in the Cx36 KO mice was not primarily mediated by their lack of interneuronal gap junctions, but was rather due to pre-existing compensatory changes in these animals. Conclusions from studies comparing seizure characteristics between WT and Cx36 KO mice must be viewed with a degree of caution because of the possible confounding effect of compensatory neurophysiological changes in the genetically modified animals.
Voss
Logan J
LJ
Department of Anesthesiology, Waikato Clinical School, University of Auckland, New Zealand. Logan.Voss@waikatodhb.health.nz
Melin
Sofia
S
Jacobson
Gregory
G
Sleigh
James W
JW
D000818:Animals; D017630:Connexins / Q000235:genetics* / Q000502:physiology*; D004569:Electroencephalography; D055724:Electrophysiological Phenomena; D005045:Etomidate / Q000494:pharmacology; D005260:Female; D018756:GABA Antagonists / Q000494:pharmacology; D017629:Gap Junctions / Q000187:drug effects; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D066298:In Vitro Techniques; D008275:Magnesium Deficiency / Q000150:complications* / Q000503:physiopathology*; D008297:Male; D015767:Mefloquine / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010852:Picrotoxin / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000187:drug effects; D012640:Seizures / Q000209:etiology* / Q000503:physiopathology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*; D000097004:Gap Junction delta-2 Protein
D017630:Connexins; D005045:Etomidate; D018756:GABA Antagonists; D006993:Hypnotics and Sedatives; D015767:Mefloquine; D010852:Picrotoxin; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D000097004:Gap Junction delta-2 Protein